CSL Limited (ASX: CSL), a global leader in biotechnology and specialty therapeutics, has secured approval from the UK’s National Institute for Health and Care Excellence (NICE) for its kidney disease treatment, Sparsentan, to be used under the National Health Service (NHS) England. The regulatory green light represents a significant step forward in the company’s rare […]